iSpecimen Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
iSpecimen Inc. (ISPC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value of $32.32 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue · last filed 2024-08-06
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for the quarter ending 2024-06-30 was $23.55K, a 37.69% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for the quarter ending 2024-03-31 was $8.77K, a 69.52% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for the quarter ending 2023-12-31 was $9.33K, a 75.44% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for the quarter ending 2023-09-30 was $10.77K, a 14.36% decline year-over-year.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for fiscal 2023 was $86.67K, a 21.41% decline from fiscal 2022.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for fiscal 2022 was $110.29K, a 149.93% increase from fiscal 2021.
- iSpecimen Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period, fair value for fiscal 2021 was $44.13K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $23.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $32.32K 10-Q · filed 2024-08-06 | $41.65K derived: sum of 3 quarters · filed 2024-08-06 | $52.42K derived: sum of 4 quarters · filed 2024-08-06 | |
| 2024-03-31 | $8.77K 10-Q · filed 2024-05-07 | $18.10K derived: sum of 2 quarters · filed 2024-05-07 | $28.87K derived: sum of 3 quarters · filed 2024-05-07 | $66.67K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2023-12-31 | $9.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $20.10K derived: sum of 2 quarters · filed 2024-03-13 | $57.90K derived: sum of 3 quarters · filed 2024-03-13 | $86.67K 10-K · filed 2024-03-13 | |
| 2023-09-30 | $10.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $48.57K derived: sum of 2 quarters · filed 2023-11-02 | $77.35K 10-Q · filed 2023-11-02 | $115.33K derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-06-30 | $37.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $66.58K 10-Q · filed 2023-08-02 | $104.56K derived: sum of 3 quarters · filed 2024-03-13 | $117.14K derived: sum of 4 quarters · filed 2024-03-13 | |
| 2023-03-31 | $28.78K 10-Q · filed 2023-05-04 | $66.76K derived: sum of 2 quarters · filed 2024-03-13 | $79.34K derived: sum of 3 quarters · filed 2024-03-13 | $135.94K derived: sum of 4 quarters · filed 2024-03-13 | |
| 2022-12-31 | $37.98K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $50.56K derived: sum of 2 quarters · filed 2024-03-13 | $107.16K derived: sum of 3 quarters · filed 2024-03-13 | $110.29K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $12.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $69.18K derived: sum of 2 quarters · filed 2022-11-08 | $72.30K 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $56.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $59.73K 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $3.13K 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $44.13K 10-K/A · filed 2023-03-30 | $44.13K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |